RA
SRPT icon

Rise Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Rise Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-213
Closed -$4.11K – 1245
2025
Q3 		$4.11K Hold
213
– – ﹤0.01% 1157
2025
Q2 		$3.64K Hold
213
– – ﹤0.01% 1168
2025
Q1 		$13.6K Buy
+213
New +$22.4K 0.01% 773

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Rise Advisors's SRPT Position: Q4 2025 in Review

Rise Advisors sold out of Sarepta Therapeutics (SRPT) in Q4 2025, closing a stake of 213 shares — an estimated $4.11K sold.

Rise Advisors first reported a position in SRPT in Q1 2025 and held it in 3 quarters. The position peaked at $13.6K in Q1 2025. 347 funds tracked by Wall St. Rank hold SRPT as of Q4 2025.

  • Rise Advisors reported no remaining Sarepta Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Rise Advisors sold 213 Sarepta Therapeutics shares in Q4 2025, an estimated $4.11K.
  • Rise Advisors first reported a position in Sarepta Therapeutics in Q1 2025 and held it in 3 quarters.
  • Rise Advisors's Sarepta Therapeutics position peaked at $13.6K in Q1 2025.
  • 347 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2025.

Based on Rise Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.